Protara Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 13, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 13, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Power of Attorney (Included in signature pages)
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Protara Therapeutics, Inc. | |
| Date: March 13, 2024 | /s/ JESSE SHEFFERMAN |
|---|---|
| Jesse Shefferman President and Chief Executive Officer (on behalf of the registrant and as the registrant’s Principal Executive Officer) | |
| Date: March 13, 2024 | /s/ PATRICK FABBIO |
| Patrick Fabbio Chief Financial Officer (on behalf of the registrant and as the registrant’s Principal Financial Officer) |
KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below constitutes and appoints Jesse Shefferman and Patrick Fabbio his or her true and lawful attorney-in-fact and agent with full power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with all exhibits thereto and all documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities and Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.
| Signature | Title | Date |
|---|---|---|
| /s/ JESSE SHEFFERMAN | President and Chief Executive Officer and Director | March 13, 2024 |
| Jesse Shefferman | (Principal Executive Officer) | |
| /s/ PATRICK FABBIO | Chief Financial Officer | March 13, 2024 |
| Patrick Fabbio | (Principal Financial Officer) | |
| /s/ HANNAH FRY | Vice President, Controller | March 13, 2024 |
| Hannah Fry | (Principal Accounting Officer) | |
| /s/ LUKE BESHAR | Chairman of the Board of Directors | March 13, 2024 |
| Luke Beshar | ||
| /s/ BARRY FLANNELLY, PHARM.D. | Director | March 13, 2024 |
| Barry Flannelly, Pharm.D. | ||
| /s/ ROGER GARCEAU, M.D. | Director | March 13, 2024 |
|---|---|---|
| Roger Garceau, M.D. | ||
| /s/ JANE HUANG, M.D. | Director | March 13, 2024 |
| Jane Huang, M.D. | ||
| /s/ RICHARD LEVY, M.D. | Director | March 13, 2024 |
| Richard Levy, M.D. | ||
| /s/ GREGORY P. SARGEN | Director | March 13, 2024 |
| Gregory P. Sargen | ||
| /s/ CYNTHIA SMITH | Director | March 13, 2024 |
| Cynthia Smith | ||
| /s/ MICHAEL SOLOMON, PH.D. | Director | March 13, 2024 |
| Michael Solomon, Ph.D. | ||
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.